Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the identification, development, and commercialization of targeted medicines for life-threatening childhood and adult diseases, particularly cancers, in the United States. Its lead product, OJEMDA (tovorafenib), is an oral, brain-penetrant type II RAF kinase inhibitor approved for pediatric patients with relapsed or refractory BRAF fusion or rearrangement-positive low-grade glioma (pLGG). The company advances tovorafenib in frontline settings through partnerships like with Ipsen for ex-U.S. rights. Day One Biopharmaceuticals, Inc. also develops DAY301, a PTK7-targeted antibody-drug conjugate for advanced solid tumors, and Emi-Le (emiltatug ledadotin), a B7-H4-targeted antibody-drug conjugate for breast, ovarian, endometrial cancers, and adenoid cystic carcinoma. These pipeline assets are in Phase 1 clinical trials. Founded in 2018 and headquartered in the United States, the company employs a 'search & development' strategy led by oncology experts to deliver first- or best-in-class therapies addressing unmet needs in pediatric and adult oncology.